These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38575714)

  • 1. Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response.
    Esposito M; Minnai F; Copetti M; Miscio G; Perna R; Piepoli A; De Vincentis G; Benvenuto M; D'Addetta P; Croci S; Baldassarri M; Bruttini M; Fallerini C; Brugnoni R; Cavalcante P; Baggi F; Corsini EMG; Ciusani E; Andreetta F; Dragani TA; Fratelli M; Carella M; Mantegazza RE; Renieri A; Colombo F
    Commun Med (Lond); 2024 Apr; 4(1):63. PubMed ID: 38575714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association studies of response and side effects to the BNT162b2 vaccine in Italian healthcare workers: Increased antibody levels and side effects in carriers of the HLA-A*03:01 allele.
    Magri C; Marchina E; Sansone E; D'Adamo AP; Cappellani S; Bonfanti C; Terlenghi L; Biasiotto G; Zanella I; Sala E; Caruso A; Lombardo M; Gasparini P; De Palma G; Gennarelli M
    HLA; 2023 Dec; 102(6):707-719. PubMed ID: 37469131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host genetics impact on SARS-CoV-2 vaccine-induced immunoglobulin levels and dynamics: The role of
    Gemmati D; Longo G; Gallo I; Silva JA; Secchiero P; Zauli G; Hanau S; Passaro A; Pellegatti P; Pizzicotti S; Serino ML; Singh AV; Tisato V
    Front Genet; 2022; 13():1028081. PubMed ID: 36531241
    [No Abstract]   [Full Text] [Related]  

  • 4. An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine.
    Khor SS; Omae Y; Takeuchi JS; Fukunaga A; Yamamoto S; Tanaka A; Matsuda K; Kimura M; Maeda K; Ueda G; Mizoue T; Ujiie M; Mitsuya H; Ohmagari N; Sugiura W; Tokunaga K
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
    Yürüker Ö; Yetkin O; Güvenir M
    Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
    Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
    Mentzer AJ; O'Connor D; Bibi S; Chelysheva I; Clutterbuck EA; Demissie T; Dinesh T; Edwards NJ; Felle S; Feng S; Flaxman AL; Karp-Tatham E; Li G; Liu X; Marchevsky N; Godfrey L; Makinson R; Bull MB; Fowler J; Alamad B; Malinauskas T; Chong AY; Sanders K; Shaw RH; Voysey M; ; Snape MD; Pollard AJ; Lambe T; Knight JC
    Nat Med; 2023 Jan; 29(1):147-157. PubMed ID: 36228659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
    Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K
    Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine.
    Farid E; Herrera-Uribe J; Stevenson NJ
    Front Immunol; 2022; 13():817597. PubMed ID: 35711448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile.
    Díaz-Dinamarca DA; Díaz P; Barra G; Puentes R; Arata L; Grossolli J; Riveros-Rodriguez B; Ardiles L; Santelises J; Vasquez-Saez V; Escobar DF; Soto D; Canales C; Díaz J; Lamperti L; Castillo D; Urra M; Zuñiga F; Ormazabal V; Nova-Lamperti E; Benítez R; Rivera A; Cortes CP; Valenzuela MT; García-Escorza HE; Vasquez AE
    Front Public Health; 2023; 11():1229045. PubMed ID: 37693706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-induced SARS-CoV-2 antibody response: the comparability of S1-specific binding assays depends on epitope and isotype discrimination.
    Schest S; Langer C; Stiegler Y; Karnuth B; Arends J; Stiegler H; Masetto T; Peter C; Grimmler M
    Front Immunol; 2023; 14():1257265. PubMed ID: 37965324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.
    Angyal A; Longet S; Moore SC; Payne RP; Harding A; Tipton T; Rongkard P; Ali M; Hering LM; Meardon N; Austin J; Brown R; Skelly D; Gillson N; Dobson SL; Cross A; Sandhar G; Kilby JA; Tyerman JK; Nicols AR; Spegarova JS; Mehta H; Hornsby H; Whitham R; Conlon CP; Jeffery K; Goulder P; Frater J; Dold C; Pace M; Ogbe A; Brown H; Ansari MA; Adland E; Brown A; Chand M; Shields A; Matthews PC; Hopkins S; Hall V; James W; Rowland-Jones SL; Klenerman P; Dunachie S; Richter A; Duncan CJA; Barnes E; Carroll M; Turtle L; de Silva TI;
    Lancet Microbe; 2022 Jan; 3(1):e21-e31. PubMed ID: 34778853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine.
    Ragone C; Meola S; Fiorillo PC; Penta R; Auriemma L; Tornesello ML; Miscio L; Cavalcanti E; Botti G; Buonaguro FM; Bianchi A; Buonaguro L; Tagliamonte M
    Front Immunol; 2021; 12():734689. PubMed ID: 34386018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.